BNET Industries

Market Cap:$3.9B
Last Fiscal Year Sales:$259.0M
  • Public
  • US
Dow Jones Description

Developer of Bio-Pharmaceutical Products for Treatment of Heart Disease & Inflammation, Immune System Diseases & Cancer

CEO, Treasurer & Secretary
Leonard Bell
Number of Employees 504
Contact Information

352 Knotter Dr

Cheshire, Connecticut 06410-1138

www.alexionphar...

(203) 272-2596

NAICS Code Pharmaceutical Preparation Manufacturing: 325412

Recent Events

  • Bank of America Initiates Coverage on Alexion Pharmaceuticals ALXN with a Neutral

    10/30/09 - Bond / Stock Rating - View Story

  • Alexion profit jumps 36% on Soliris sales

    10/24/09 - Financial Announcement - View Story

  • Citi analyst upgrades Alexion shares to 'Buy'

    9/01/09 - Bond / Stock Rating - View Story

  • Alexion Pharmaceuticals ALXN Upgrade Alert, Watch for 12% Technical Uptrend Continuation

    9/01/09 - Bond / Stock Rating - View Story

  • Alexion profit up sixfold on Soliris sales

    7/27/09 - Financial Announcement - View Story

  • Soliris sales boost Alexion earnings

    7/24/09 - Financial Announcement - View Story

News & Analysis

alexion pharmaceuticals inc. - All News and Analysis

Decision Makers

Name (plus bio) Position
Leonard Bell CEO, Treasurer & Secretary
Russell P. Rother Chief Scientific Officer
Scott Phillips Chief Accounting Officer & Controller
Vikas Sinha CFO & Senior Vice President
Stephen P. Squinto Executive Vice President & Head, Res
David L. Hallal Senior Vice President, US Commercial Operations
Katherine S. Bowdish Senior Vice President
M. Stacy Hooks Senior Vice President, Technology Operations
Nancy C. Motola Senior Vice President, Quality & Regulatory Affairs
Patrice Coissac Senior Vice President
Scott A. Rollins Senior Vice President, Drug Dev & Project Mgmt
Thomas I.H. Dubin General Counsel & Senior Vice President
Barry P Luke Vice President, Finance & Assistant Secretary
Daniel N. Caron Vice President, Site Operations & Engineering
Eric Grinstead Vice President, United States Access Services
Glenn Melrose Vice President, HR
R. Douglas Norby Director
Ginger More Investor

Board of Directors

Name (plus bio) Position
Alvin S Parven Board of Directors
Joseph A. Madri Board of Directors
Larry L Mathis Board of Directors
Max Link Board of Directors
Ruedi E. Waeger Board of Directors

Leonard Bell, M.D. is the principal founder of Alexion, and has been a director of Alexion since February 1992 and the Company's President and Chief Executive Officer, Secretary and Treasurer from January 1992. In April 2002, the title of President was transferred to David Keiser. From 1991 to 1992, Dr. Bell was an Assistant Professor of Medicine and Pathology and co-Director of the program in Vascular Biology at the Yale University School of Medicine. From 1990 to 1992, Dr. Bell was an attending physician at the Yale-New Haven Hospital and an Assistant Professor in the Department of Internal Medicine at the Yale University School of Medicine. Dr. Bell was a recipient of the Physician Scientist Award from the National Institutes of Health and Grant-in-Aid from the American Heart Association as well as various honors and awards from academic and professional organizations. His work has resulted in more than 20 scientific publications and 9 patent applications. Dr. Bell was also a director of The Medicines Company from May 2000 until April 2005. He also served as a director of the Biotechnology Research and Development Corporation from 1993 to 1997. Dr. Bell received his A.B. from Brown University and M.D. from Yale University School of Medicine. Dr. Bell is currently an Adjunct Assistant Professor of Medicine and Pathology at Yale University School of Medicine.

Organization Position Status
Alxn Chief Executive Officer, Secretary, Treasurer, Director Current
Alexion Pharmaceuticals, Inc. CEO, Treasurer & Secretary Current
Alexion Pharmaceuticals, Inc. Board of Directors Current
Alxn Principal Founder Former
Yale University School of Medicine Co-Director of The Program Former
Yale-New Haven Hospital Physician Former
Pathology Inc. Assistant Prof Former
Yale University School of Medicine Assistant Prof Former
American Heart Association, Inc. Scientist Former
Biotechnology Research and Development Corporation Director Former
Yale University School of Medicine M.D. Former
Brown University A.B. Former

Russell P. Rother, Ph.D. currently serves as Senior Vice President and Chief Scientific Officer at Alexion. Dr. Rother was Senior Vice President of Research from 2005 to 2007, Vice President, Discovery Research from 2001 to 2005, Senior Director of Discovery Research from 1999 to 2001, Director of Gene Technologies from 1996 to 1999, Senior Staff Scientist from 1994 to 1996 and Staff Scientist from 1992 to 1994. As one of the original scientists at Alexion, Dr. Rother played a critical role in the engineering and development of Alexion's current antibody therapeutics and continues to lead discovery efforts in the identification of new indications and targets. Dr. Rother was also primarily responsible for the initiation of the paroxysmal nocturnal hemoglobinuria (PNH) program and played a major role in its development to date. Prior to 1992, Dr. Rother was a Postdoctoral Research Fellow in the Department of Immunobiology at Yale University School of Medicine. Dr. Rother's work has led to over 50 scientific papers and patents in the fields of hematology, complement biology, transplantation, autoimmunity, and gene therapy. Dr. Rother received a Ph.D. in Microbiology and Immunology from the University of Oklahoma Health Sciences Center in conjunction with the Oklahoma Medical Research Foundation.

Organization Position Status
Alxn Senior Vice President and Chief Scientific Officer Current
Alxn Senior Vice President, Research Former
Gene Technologies Limited Senior Vice President of Research Former
Alexion Pharmaceuticals, Inc. Senior Vice President, Res Former
Gene Technologies Limited Vice President, Discovery Research Former
Gene Technologies Limited Senior Director of Discovery Research Former
Yale University School of Medicine Fellow Department of Immunobiology Former
Gene Technologies Limited Director Former
University of Oklahoma Health Sciences Center Ph.D. In Microbiology and Immunology Former
Southwestern Oklahoma State University B.S. In Biology Former

Organization Position Status
Alexion Pharmaceuticals, Inc. Chief Accounting Officer & Controller Current

Vikas Sinha has served as Senior Vice President and Chief Financial Officer for Alexion since 2005. In this role, Mr. Sinha has responsibility for global financial management, corporate and strategic development, communications and information technology activities. He is also responsible for market development in Japan. Previously, Mr. Sinha spent 11 years with Bayer AG, where he held numerous positions in the United States, Japan, Germany and Canada, including, most recently, the position of Vice President and Chief Financial Officer of Bayer Pharmaceutical Corporation, USA. During his time with Bayer, Mr. Sinha held responsibility for a variety of business functions, including financial and business risk management, strategic planning, contracting, customer services, information systems, and supply chain and site administration in North America. He also served as Vice President and Chief Financial Officer of Bayer Yakuhin Ltd., in Japan, Manager of Mergers and Acquisitions with Bayer AG in Germany, and began his career at Bayer in Toronto in a healthcare executive development program. Prior to Bayer, Mr. Sinha also held several positions of increasing responsibilities with ANZ Bank and Citibank in South Asia. Mr. Sinha holds a master's degree in business administration from the Asian Institute of Management. He is also a qualified Chartered Accountant from the Institute of Chartered Accountants of India.

Organization Position Status
Alexion Pharmaceuticals, Inc. CFO & Senior Vice President Current
Alxn Senior Vice President and Chief Financial Officer Current
Bayer Yakuhin, Ltd. Chief Financial Officer Former
Bayer Yakuhin, Ltd. Vice President Former
Asian Institute of Management Masters of Business Administration Former

Stephen P. Squinto, Ph.D. is a founder of Alexion and has been Executive Vice President and Head of Research since August 2000. He held the positions of Senior Vice President and Chief Technical Officer from March 1998 to July 2000, Vice President of Research, Molecular Sciences, from August 1994 to March 1998, Senior Director of Molecular Sciences from July 1993 to July 1994, and Director of Molecular Development from 1992 to July 1993. From 1989 to 1992, Dr. Squinto held various positions at Regeneron Pharmaceuticals, Inc. most recently serving as Senior Scientist and Assistant Head of the Discovery Group. From 1986 to 1989, Dr. Squinto was an Assistant Professor of Biochemistry and Molecular Biology at Louisiana State University Medical Center. Dr. Squinto's work has led to over 70 scientific papers in the fields of gene regulation, growth factor biology and gene transfer. Dr. Squinto's work is primarily in the fields of regulation of eukaryotic gene expression, mammalian gene expression systems and growth receptor and signal transduction biology. Dr. Squinto served as a Director of the Biotechnology Research and Development Corporation, a biotechnology consortium, from 1997 to 2003. Dr. Squinto received his B.A. in Chemistry and Ph.D. in Biochemistry and Biophysics from Loyola University of Chicago.

Organization Position Status
Alxn Executive Vice President and Head of Research Current
Alexion Pharmaceuticals, Inc. Executive Vice President & Head, Res Current
Alxn Founder Former
Louisiana State University Medical Center Assistant Professor of Biochemistry and Molecular Biology Former
Regeneron Pharmaceuticals, Inc. Senior Scientist Former
Biotechnology Research and Development Corporation Director Former
Loyola University Chicago Ph.D. In Biochemistry and Biophysics Former
Loyola University Chicago B.A. In Chemistry Former

"David Hallal is Senior Vice President of Commercial Operations, Americas for Alexion Pharmaceuticals. In this position, Mr. Hallal is responsible for all commercial functions in North and South America, including marketing, sales, reimbursement, health policy and product access services. Mr. Hallal joined Alexion in 2006 to build the company's U.S. commercial organization, and he led the highly successful U.S. launch of the company's first product, Soliris (eculizumab). Mr. Hallal is also preparing the company to enter additional markets such as Canada, Mexico and Brazil. Before joining Alexion, Mr. Hallal served as Vice President, Sales at OSI Eyetech where he led the U.S. launch of Macugen, the first-in-class anti-VEGF therapy for age-related macular degeneration. Prior to OSI Eyetech, Mr. Hallal was Senior Director of Sales for Biogen Idec's Immunology Sales Team, where he built a sales organization dedicated to the launch of the first-in-class biologic Amevive for psoriasis. Beginning in 1992, Mr. Hallal worked for more than ten years at Amgen, where he held various leadership positions focusing on the blockbuster brands Epogen, Neupogen, Neulasta and Aranesp in the hematology and oncology marketplace. His roles included National Account Manager, Southeast Oncology Sales Director and Oncology Health Systems Sales Director, and Director of Oncology National Accounts, where he was responsible for forging relationships with many of the largest managed care organizations in the United States. Mr. Hallal received a bachelor of arts from the University of New Hampshire. "

Organization Position Status
Alexion Pharmaceuticals, Inc. Senior Vice President, US Commercial Operations Current

Organization Position Status
Alexion Antibody Technologies, Inc. President Current
Alxn Senior Vice President of Antibody Discovery and President Current
Alexion Pharmaceuticals, Inc. Senior Vice President Current
Alexion Antibody Technologies, Inc. Senior Vice President Former
Columbia University College of Physicians and Surgeons Ph.D. In Molecular Genetics Former

"Dr. Stacy Hooks is Senior Vice President of Technical Operations at Alexion. In this role, Dr. Hooks leads the manufacturing efforts, manages the supply chain, oversees product process and analytical development, and has responsibility for the company's quality control and quality assurance functions. Dr. Hooks joined Alexion in 2002, and has held a variety of positions, including Director of Quality Control (2002-2004), Senior Director of Manufacturing and Technical Services (2004) and Executive Director of Manufacturing and Technical Services (2004-2006), and Vice President of Manufacturing and Technical Service (2007-2008). Previously, Dr. Hooks was Director of Quality Assurance at Pharmacia, Inc. Dr. Hooks has also served as Director of Quality at QIAGEN, Inc., a multinational life sciences company, Associate Director of Quality Control at MedImmune, Inc., a biopharmaceutical firm, a Quality Scientist with Biogen-IDEC. He began his career at CytoTherapeutics. Dr. Hooks received his bachelor of science in chemistry from Murray State University in Kentucky and a doctorate in chemistry from Emory University in Atlanta, Georgia. "

Organization Position Status
Alexion Pharmaceuticals, Inc. Senior Vice President, Technology Operations Current
Alexion Pharmaceuticals, Inc. Vice President, Manufacturing & Technology Services Former
Alexion Pharmaceuticals, Inc. Executive Director, Manufacturing, Technology Services Former
Pharmacia Corporation Director of Quality Assurance Former
Emory University Ph.D in Chemistry Former
Murray State University B.S. in Chemistry Former

Organization Position Status
Alxn Senior Vice President, Regulatory Affairs and Quality Current
Alexion Pharmaceuticals, Inc. Senior Vice President, Quality & Regulatory Affairs Current
Squibb Corporation Research Investigator Former
Abbott Laboratories Former
Central Connecticut State University M.S. and Ph Former
University of Rhode Island M.S. and Ph Former
Central Connecticut State University B.A. In Chemistry Former

Organization Position Status
Alxn Senior Vice President, General Manager and President of Alexion Europe Sas Current
Alexion Pharmaceuticals, Inc. Senior Vice President Current
Pfizer Inc. Former
Monsanto Company Former
Pharmacia Corporation Former
Pharmacia & Upjohn Former
Sandoz Former

Scott A. Rollins, Ph.D. is a co-founder of Alexion and has been Senior Vice President, Drug Development and Project Management since September 2002. From August 2000 to September 2002, Dr. Rollins was Vice President, Drug Development and Project Management. Dr. Rollins was Senior Director of Project Management and Drug Development from August 1999 to July 2000, Senior Director of Complement Biology from 1997 to 1999, Director of Complement Biology from 1996 to 1997, Principal Scientist from 1994 to 1996, and Staff Scientist from 1992 to 1994. Over the past 15 years at Alexion, Dr. Rollins has played a key role in the discovery, characterization and development of eculizumab and pexelizumab. Prior to 1992, Dr. Rollins was a postdoctoral research fellow in the Department of Immunobiology at Yale University School of Medicine. Dr. Rollins is recognized as a leader in the field of Complement Biology and his work has led to over 50 scientific papers and patents. He received his B.S. in Cytotechnology and Ph.D. in Microbiology and Immunology from the University of Oklahoma Health Sciences Center.

Organization Position Status
Alxn Senior Vice President, Drug Development and Project Management Current
Alexion Pharmaceuticals, Inc. Senior Vice President, Drug Dev & Project Mgmt Current
Alxn Co-Founder Former
Yale University School of Medicine Fellow Department of Immunobiology Former
University of Oklahoma Health Sciences Center Ph.D. In Microbiology and Immunology Former
University of Oklahoma Health Sciences Center B.S. In Cytotechnology Former

Thomas I.H. Dubin, J.D. has been Senior Vice President and General Counsel since August 2005. He was Vice President and General Counsel from January 2001 to July 2005. From February 1999 to September 2000 he served as Vice President, General Counsel and Secretary for ChiRex Inc., a NASDAQ-traded international corporation providing advanced process development services and specialty manufacturing to the pharmaceutical industry, which in September 2000 was acquired by and merged into Rhodia. From 1992 to 1999, Mr. Dubin held various positions with Warner-Lambert Company, including Assistant General Counsel, Pharmaceuticals. Prior to his tenure with Warner-Lambert, Mr. Dubin was a corporate attorney for five years with Cravath, Swaine & Moore in New York. Mr. Dubin received his J.D. from New York University and his B.A., cum laude, from Amherst College.

Organization Position Status
Alxn Senior Vice President and General Counsel Current
Alexion Pharmaceuticals, Inc. General Counsel & Senior Vice President Current
Warner-Lambert Company Former
New York University J.D. Former
Amherst College B.A. Former

Array

Organization Position Status
Alxn Vice President, Finance, Assistant Secretary Current
University of Connecticut M.B.A. In Management Former
Yale University B.A. In Economics Former

"Daniel Caron is Executive Director of Operations and Engineering for Alexion, with responsibility for managing the engineering and operations of the company's research, manufacturing and administrative facilities. Mr. Caron has been involved in the operation of Alexion since 1992, when he joined the company as Operations Manager. Over the next several years, Mr. Caron assumed roles of increasing responsibility, including Senior Operations Manager (1993-1996), Director of Operations (1996-1998) and Senior Director of Operations and Engineering (1998-2004). Before joining Alexion, Mr. Caron was a research scientist at Imclone Systems, Inc., a biopharmaceutical firm. Mr. Caron received his bachelor of arts in biology from Adelphi University in New York, where he graduated with honors, and a master's degree in biomedical engineering from Polytechnic University of New York."

Organization Position Status
Alexion Pharmaceuticals, Inc. Vice President, Site Operations & Engineering Current
Alxn Executive Director, Operations and Engineering Current
Alxn Board of Directors Current
Alexion Pharmaceuticals, Inc. Executive Director, Engineering & Operations Former
ImClone Systems Incorporated research scientist Former
Polytechnic University M.S. In Biomedical Engineering Former
Adelphi University B.A. In Biology Former
Polytechnic University B.A. In Biology Former

Organization Position Status
Alexion Pharmaceuticals, Inc. Vice President, United States Access Services Current

"Glenn Melrose is Vice President of Human Resources for Alexion, a position he has held since joining the company in 2007. In this role, Mr. Melrose is responsible for developing and implementing the company's human resource strategy to support its growth in the United States and major markets around the world. He ensures that existing and newly opened Alexion operations receive appropriate support based on local needs. Previously, Mr. Melrose was Vice President of Human Resources at NPS Pharmaceuticals. For 16 years, he also held roles of increasing responsibility at Amersham Diagnostics, including leading the worldwide Human Resources function for Amersham Biosciences. Mr. Melrose began his career as a scientist at the University of Maryland Cancer Center and Becton Dickinson, a medical technology company. Mr. Melrose received a bachelor of science in biology from Washington and Lee University in Virginia and a master's degree in experimental biology from the University of Maryland. "

Organization Position Status
Alexion Pharmaceuticals, Inc. Vice President, HR Current

Array

Organization Position Status
Alxn Director Current
Pension Services, Inc. Former
Aetna Inc. Chairman Former
Northeastern University B.A. Former

Array

Organization Position Status
Yale University School of Medicine Faculty Current
Alexion Pharmaceuticals, Inc. Board of Directors Current
Alxn Director Current
Indiana University M.D. Former
St. John's University M.S. In Biology Former
Indiana University B.S. Former
St. John's University B.S. Former

Organization Position Status
Proxyvotenow Independent Director Current
Diane Peterson Executive Consultant Current
Larry Mathis Current
Harris County Hospital District Foundation Vice-Chairman Current
Alexion Pharmaceuticals, Inc. Board of Directors Current
Proxyvotenow Board of Directors Current
Alxn Director Current
Methodist Health Care System Chief Executive Officer Former
D.Co executive consultant Former
American Hospital Association Chairman of the Board Former
Washington University M.A. Degree In Health Administration Former
Pittsburg State University B.A. Degree In Social Sciences Former

R. Douglas Norby joined Tessera as chief financial officer and senior vice president in July 2003. An industry veteran with more than 35 years in the technology sector, Norby has held numerous executive management positions with such prominent companies as LSI Logic, Mentor Graphics and Syntex Corporation. Most recently, he was chief financial officer of Zambeel, Inc., a provider of enterprise-class network storage solutions. Norby has served on the boards of entertainment company Lucasfilm Ltd., where he was also president and chief operating officer, and Recordati, S.p.A., an Italian pharmaceutical company. He currently serves on three public company boards: LSI Logic, Alexion Pharmaceuticals, and STATS ChipPAC. Norby holds a bachelor's degree in economics from Harvard University and an M.B.A. from Harvard Business School.

Organization Position Status
Tessera Chief Financial Officer Current
S2IO, Inc. Chief Financial Officer and Senior Vice President Current
Magnachip Semiconductor Ltd. Director and Chairman of the Audit Committee Current
Tessera Technologies, Inc. Consultant Current
Alxn Board of Directors Current
S2IO, Inc. Board of Directors Current
Jazz Semiconductor, Inc. Board of Directors Current
Alexion Pharmaceuticals, Inc. Director Current
Nexx Systems, Inc. Director Current
STATS ChipPAC Ltd. Director Current
Novalux, Inc. Chief Financial Officer Former
Tessera Technologies, Inc. Chief Financial Officer Former
Syntex Corporation Chief Financial Officer Former
Zambeel.Com Chief Financial Officer Former
Syntex Corporation Senior Vice President Former
Novalux, Inc. Senior Vice President Former
Tessera Technologies, Inc. Senior Vice President Former
Zambeel.Com Senior Vice President Former
Tessera Senior Vice President Former
Tessera Consultant Former
Itel Corporation Former
Recordati Corporation Board of Directors Former
Magnachip Semiconductor Ltd. Director Former
Harvard University Bachelor's Degree In Economics Former

Ruedi E. Waeger, Ph.D. has been a director of Alexion since March 2005. Dr. Waeger has spent the past 30 years in the pharmaceutical and therapeutic protein industry. Most recently, he was President and Chief Executive Officer of Aventis Behring L.L.C., a global plasma therapeutics product business which was acquired by CSL Ltd in 2004 to form ZLB Behring. While at Aventis Behring, Dr. Waeger played a key role in guiding the company as it refined its product pipeline and extensive manufacturing facilities. Dr. Waeger became the head of Aventis Behring following the merger of the owners of Centeon L.L.C., a leader in plasma proteins, where Dr. Waeger was Chief Executive Officer. Prior thereto, Dr. Waeger was President and Chief Executive Officer of ZLB Central Laboratories, Blood Transfusion Service of Swiss Red Cross, and before that spent more than 20 years at Sandoz Ltd., where he had consecutive worldwide responsibilities for Strategic Research and Development Planning, Human Resource Management, and Marketing, including responsibility for three global product launches. Dr. Waeger currently sits on the Board of Talecris Biotherapeutics, Inc.. He earned a Ph.D. in Biochemistry from the Swiss Federal Institute of Technology.

Organization Position Status
Alexion Pharmaceuticals, Inc. Board of Directors Current

Ginger M. More is currently a Special Limited Partner of Oak Investment Partners ( Oak ) and had been a General Partner or Managing Member since 1980. Oak has raised ten venture capital partnerships with a total of $4.2 billion in committed capital. Oak has sponsored over 350 companies with aggregate annual revenues in excess of $100 billion. Oak s most recent fund, Oak X, was closed on February 28, 2001 with a total capitalization of $1.6 billion. Ginger joined Oak at its inception in 1978 after ten years at Wright Investor's Service. She has sponsored investments in and/or served on the boards of numerous healthcare and information technology companies including the following publicly-traded companies, Alexion Pharmaceuticals, Inc., Alkermes, Inc., Compaq Computer Corporation, Dyax Corporation, Esperion Therapeutics, Inc., Genzyme Corporation, Octel Communications Corporation, OraPharma, Inc., Osteotech Inc., Pharmacopeia, Inc. and Ribozyme Pharmaceuticals, Inc. Ginger studied Mathematics at the University of Bridgeport and became a Chartered Financial Analyst in 1978.

Organization Position Status
Kbl Healthcare, Inc. Special Limited Partner of Oak Investment Partners Current
Ribozyme Pharmaceuticals Inc Current
Stratus Inc Current
Tengion, Inc. Board of Directors Current
University of Connecticut Board of Directors Current
Uconn R&D Corporation Board of Directors Current
Esperion Therapeutics, Inc. Investor Current
Alexion Pharmaceuticals, Inc. Investor Current
Osteotech, Inc. Investor Current
Dyax Corp. Investor Current
Orapharma, Inc. Investor Current
Alkermes, Inc. Investor Current
Compaq Computers Investor Current
Pharmacopeia Drug Discovery Inc. Investor Current
Genzyme Corporation Investor Current
Octel Communications Investor Current
Oak Investment Partners Founder Former
University of Bridgeport Chartered Financial Analyst Former
Winthrop Corporation Former
Psychiatric Solutions, Inc. Board of Directors Former
Sopherion, Inc. Board of Directors Former
University of Bridgeport Mathematics Former

Executive News

  • Alexion says open to buyout, not partnerships

    Imaging Economics - 8/23/09 - View Story

  • European Commission and U.S. FDA Grant Alexion's Soliris(R) (eculizumab) Orphan Drug...

    Forbes.com - 8/06/09 - View Story

  • European Commission and U.S. FDA Grant Alexions Soliris (eculizumab) Orphan Drug Designation for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS)

    Business Wire - 8/06/09 - View Story

advertisement
     ALXN $45.14 +0.43 (0.96% )
Average Volume 657,528
Shares Outstanding 88.57M
Market Cap 4.0B
Year High 48.93
Year Low 30
Earnings Per Share 0.81
P/E Ratio 55.73
Dividend N/A
Yield N/A
advertisement